We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine

Postvaccination immune-mediated hepatitis: what do we really know?

    Angioletta Lasagna

    *Author for correspondence: Tel.: +39 038 250 2287;

    E-mail Address: a.lasagna@smatteo.pv.it

    Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, 27100, Italy

    ,
    Paolo Pedrazzoli

    Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, 27100, Italy

    Department of Internal Medicine & Medical Therapy, University of Pavia, Viale Camillo Golgi 19, Pavia, 27100, Italy

    ,
    Raffaele Bruno

    Department of Clinical Surgical Diagnostic & Pediatric Sciences, University of Pavia, Viale Camillo Golgi 19, Pavia, 27100, Italy

    Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, 27100, Italy

    &
    Paolo Sacchi

    Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, 27100, Italy

    Published Online:https://doi.org/10.2217/imt-2023-0038

    Tweetable abstract

    The percentage of patients with immune-mediated vaccine-associated hepatitis is minimal compared with the number of patients vaccinated worldwide.

    Papers of special note have been highlighted as: • of interest; •• of considerable interest

    References

    • 1. Lasagna A, Lenti MV, Cassaniti I, Sacchi P. Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report. Immunotherapy 14(12), 915–925 (2022).
    • 2. Wong CKH, Mak LY, Au ICH et al. Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines. J. Hepatol. 77(5), 1339–1348 (2022).
    • 3. Chow KW, Pham NV, Ibrahim BM, Hong K, Saab S. Autoimmune hepatitis-like syndrome following COVID-19 vaccination: a systematic review of the literature. Dig. Dis. Sci. 67(9), 4574–4580 (2022). • This paper illustrated how the approved vaccines trigger an autoimmune hepatitis-like syndrome.
    • 4. Codoni G, Kirchner T, Engel B et al. Histological and serological features of acute liver injury after SARS-CoV-2 vaccination. JHEP Rep. 5(1), 100605 (2022). •• A very useful update on the current knowledge of histological features of acute liver injury after COVID-19 vaccines.
    • 5. Boettler T, Csernalabics B, Salié H et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. J. Hepatol. 77(3), 653–659 (2022).
    • 6. Ozaka S, Kobayashi T, Mizukami K, Murakami K. COVID-19 vaccination and liver disease. World J. Gastroenterol. 28(48), 6791–6810 (2022).
    • 7. Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front. Immunol. 11, 617089 (2021).
    • 8. Maurice NJ, McElrath MJ, Andersen-Nissen E, Frahm N, Prlic M. CXCR3 enables recruitment and site-specific bystander activation of memory CD8+ T cells. Nat. Commun. 10(1), 4987 (2019).
    • 9. Hao Y, O'Neill P, Naradikian MS, Scholz JL, Cancro MP. A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood 118(5), 1294–1304 (2011).
    • 10. Sachinidis A, Garyfallos A. COVID-19 vaccination can occasionally trigger autoimmune phenomena, probably via inducing age-associated B cells. Int. J. Rheum. Dis. 25(1), 83–85 (2022).
    • 11. Zheng H, Zhang T, Xu Y, Lu X, Sang X. Autoimmune hepatitis after COVID-19 vaccination. Front. Immunol. 13, 1035073 (2022).
    • 12. Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J. Autoimmun. 47, 1–16 (2013).
    • 13. Salemi S, D'Amelio R. Could autoimmunity be induced by vaccination? Int. Rev. Immunol. 29(3), 247–269 (2010).
    • 14. Lasagna A, Cassaniti I, Sacchi P et al. The “hit-and-run” strategy and the viral carcinogenesis. Future Oncol. doi: 10.2217/fon-2022-1171 (2023) (Epub ahead of print).
    • 15. Christen U, Hintermann E. Pathogens and autoimmune hepatitis. Clin. Exp. Immunol. 195(1), 35–51 (2019).
    • 16. Pacheco Y, Acosta-Ampudia Y, Monsalve DM, Chang C, Gershwin ME, Anaya JM. Bystander activation and autoimmunity. J. Autoimmun. 103, 102301 (2019).
    • 17. Tagliamonte M, Buonaguro L. The impact of antigenic molecular mimicry on anti-cancer T-cell immune response. Front. Oncol. 12, 1009247 (2022).
    • 18. Howard FHN, Kwan A, Winder N, Mughal A, Collado-Rojas C, Muthana M. Understanding immune responses to viruses–do underlying Th1/Th2 cell biases predict outcome? Viruses 14(7), 1493 (2022).
    • 19. Bessone F, Bjornsson ES. Checkpoint inhibitor-induced hepatotoxicity: role of liver biopsy and management approach. World J. Hepatol. 14(7), 1269–1276 (2022).
    • 20. Trontzas IP, Kyriakoulis KG, Vathiotis IA et al. Vaccine-related autoimmune hepatitis: emerging association with SARS-CoV-2 vaccination or coincidence? Vaccines (Basel) 10(12), 2073 (2022).